3 results about "Idarubicin" patented technology

A pharmaceutical composition for preventing and / or treating tumors, which pharmaceutical composition contains the following topoisomerase II inhibitors as active ingredients: doxorubicin, etoposide, idarubicin, amsacrine, aclarubicin, teniposide, epirubicin, and pirarubicin. The pharmaceutical composition, compared with any one of the components therein, has significantly enhanced tumor inhibitory effects and significantly reduced toxic side effects, wherein a synergistic effect is present among the components.

The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicine. The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia. The application of idarubicin in BPH treatment is found and confirmed for the first time: (1) the specificity effectiveness of BPH, preferably gland proliferation type BPH, is verified, and the intervention effect of idarubicin on a core target TP63 and gland proliferation is clear; (2) the regulation and control effect on prostate volume and gland hyperplasia is supported through in-vivo experimental data; and (3) curative effect verification at a clinical level is carried out, and a clinical application path of subtype screening-drug intervention-curative effect evaluation is established, so that transformation in BPH precise treatment is facilitated. According to the research, through a complete evidence chain of cell, animal and multi-center clinical retrospective research, the treatment value of idarubicin on BPH, especially gland proliferation type BPH, is verified, and the blank in the field is filled.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.